title: FDG PET/CT in the management of colorectal and anal cancers.
abstract: OBJECTIVE
  CT remains the imaging modality of choice in the diagnosis of colorectal cancer (CRC) and anal cancer. However, advances in imaging have expanded the role of MRI and PET/CT. This article focuses on the evolving role of FDG PET/CT in the diagnosis, radiation therapy planning, therapy assessment, and posttherapy monitoring of CRC and anal cancer.
  
  
  CONCLUSIONS
  FDG PET/CT is a valuable imaging modality that impacts the clinical management of patients with CRC and those with anal cancer.
authors.affiliation: 1 Boston University School of Medicine, Boston, MA.
authors.forename: Ankit
authors.initials: A
authors.lastname: Agarwal
authors.forename: Charles
authors.initials: C
authors.lastname: Marcus
authors.forename: Jennifer
authors.initials: J
authors.lastname: Xiao
authors.forename: Prachi
authors.initials: P
authors.lastname: Nene
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Kachnic
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
mesh_terms: D000328:Adult; D000368:Aged; D001005:Anus Neoplasms / Q000175:diagnosis*; D015179:Colorectal Neoplasms / Q000175:diagnosis*; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008875:Middle Aged; D064847:Multimodal Imaging / Q000379:methods*; D009367:Neoplasm Staging / Q000379:methods; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods*
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: PET/CT; anal cancer; colorectal cancer; radiation therapy planning; therapy assessment